| Heading: |
Neuroendocrine Cancer: Radiotherapy |
| Question ID: |
1796164 |
| UIN: |
47206 |
| House: |
Commons |
| Date tabled: |
2025-04-23 |
| Asking Member ID: |
4126 |
| Asking Member display name: |
Mary Glindon
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Mary Glindon
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 April 2025 to Question 43451 on Neuroendocrine Cancer: Radiotherapy, what recent discussions his Department has had with Integrated Care Boards on the commissioning of s |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-29 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4981 |
| Answering Member display name: |
Ashley Dalton
|
| Answering Member handle: |
AshleyDalton_MP
|
| Answering Member Twitter reference: |
@AshleyDalton_MP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
NHS England commissions selective internal radiation therapy for chemotherapy refractory / intolerant metastatic colorectal cancer in adults in accordance with criteria which is available at the following link:https://www.england.nhs.uk/wp-content/uploads... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |